Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
BMC Medicine|October 7, 2014
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trialsPernelle Lavaud, Fabrice AndreBulletin Du Cancer|August 31, 2019
[Management of metastatic testicular germ cell tumors]Pernelle Lavaud, Giulia Baciarello, Karim FizaziFuture Oncology (London, England)|November 15, 2017
Atezolizumab in urothelial bladder carcinomaZineb Hamilou, Pernelle Lavaud, Yohann LoriotCurrent Oncology Reports|April 9, 2024
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate CancerGuillaume Grisay, Pernelle Lavaud, Karim FizaziExpert Review of Anticancer Therapy|March 1, 2018
Durvalumab in urothelial cancersPernelle Lavaud, Zineb Hamilou, Yohann Loriot, et al.Bulletin Du Cancer|January 2, 2018
[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma]Alice Bernard-Tessier, Clément Bonnet, Pernelle Lavaud, et al.The British Journal of Radiology|March 16, 2026
Impact of tumor volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumabVincent Legendre, Angela Botticella, Kristi Beshiri, et al.Journal for Immunotherapy of Cancer|April 22, 2017
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patientsLuc Cabel, Elika Loir, Gwenaelle Gravis, et al.Cancer Management and Research|April 5, 2021
Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to EntrectinibFrancesco Facchinetti, Antonin Levy, Samy Ammari, et al.Bulletin Du Cancer|April 23, 2021
[Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]Reda El Hazzaz, Maria Kfoury, Pernelle Lavaud, et al.Pageof 6